Rare kidney & urinary condition
Light chain deposition disease
Light chain deposition disease is a rare condition in which antibody fragments from a plasma cell clone coat the kidney's membranes - without forming amyloid - causing protein leak and progressive kidney failure unless the clone is treated.
Key points
The essentials at a glance.
What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.
-
01
It belongs to the 'monoclonal gammopathy of renal significance' (MGRS) family: a small, otherwise silent clone doing outsized kidney damage.
-
02
Presentation: protein leak (often nephrotic), kidney impairment, sometimes with heart or liver involvement.
-
03
Diagnosis needs kidney biopsy with immunofluorescence plus serum free light chain testing and marrow assessment.
-
04
Treatment is clone-directed - bortezomib-based or daratumumab-based regimens borrowed from myeloma care - even when the clone is too small to call myeloma.
-
05
Haematology and nephrology co-manage; kidney outcomes track how deeply the light chain level is suppressed. Recurrence in transplants occurs if the clone is not controlled.
Understanding it
What it is, and what happens next.
In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.
Not every dangerous plasma cell clone meets the definition of myeloma: in light chain deposition disease a modest clone secretes a light chain with an unfortunate physical chemistry, and it precipitates along the kidney's basement membranes, stiffening and destroying filters. Because standard cancer criteria are not met, the disease was historically under-treated - the modern MGRS concept exists precisely to close that gap.
The pathway that changes outcomes couples an immunofluorescence-read biopsy with free light chain assays and marrow studies, then treats the clone with anti-plasma-cell therapy regardless of its size; deep haematological responses can stabilise or improve kidney function, and are a prerequisite before kidney transplantation can sensibly be considered. In many parts of the UK, routine NHS outpatient referrals for problems like this can take several months, whereas an initial appointment with a private consultant is typically available within around two weeks.
A quiet reminder
This guide is for information, not medical advice.
Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.
Published 2026-09-27 · Next review 2027-09-27
Frequently asked
Common questions about Light chain deposition disease.
Quick, plain-English answers to what people ask us most.
-
What is light chain deposition disease?
Light chain deposition disease is a rare condition where abnormal antibody protein fragments (light chains), produced by an abnormal population of plasma cells, deposit in organs, most commonly the kidneys, impairing their function. It's related to other plasma cell disorders such as multiple myeloma.
-
What causes light chain deposition disease?
It's caused by an underlying clone of abnormal plasma cells in the bone marrow producing excess abnormal light chain proteins, which then deposit in organs and cause damage. This is often linked to an underlying condition such as monoclonal gammopathy or multiple myeloma.
-
What are the symptoms of light chain deposition disease?
Symptoms depend on which organs are affected but commonly include signs of kidney impairment such as swelling, fatigue, and reduced kidney function detected on blood tests. Heart and liver involvement can also occur in some cases, causing additional symptoms.
-
Is light chain deposition disease dangerous?
Yes, it can lead to progressive organ damage, particularly affecting the kidneys, and may progress to kidney failure if not treated. Early diagnosis and treatment of the underlying plasma cell disorder can significantly improve organ function and outcomes.
-
Is light chain deposition disease genetic?
No, it results from an acquired abnormal plasma cell population rather than being inherited. It's not something that runs in families or is passed on to children.
-
Can light chain deposition disease be treated?
Yes, treatment targets the underlying abnormal plasma cell clone using chemotherapy or other specific treatments similar to those used for multiple myeloma, which can halt or improve organ damage in many cases. Early treatment before significant organ damage occurs gives the best outcomes.
-
How is light chain deposition disease treated?
Treatment typically involves chemotherapy or targeted therapy aimed at reducing the abnormal plasma cell population producing the harmful light chains, sometimes including stem cell transplant in suitable patients. Supportive care for affected organs, particularly the kidneys, is also an important part of management.
-
How is light chain deposition disease diagnosed?
Diagnosis typically involves blood and urine tests to detect abnormal light chain proteins, a bone marrow biopsy to identify the abnormal plasma cell population, and sometimes a kidney biopsy to confirm the specific pattern of organ deposition. A haematologist usually coordinates this diagnostic work-up.
-
Light chain deposition disease vs amyloidosis — what's the difference?
Both involve abnormal light chain proteins depositing in organs and causing damage, but they differ in how the protein deposits are structured at a molecular level, which is identified through specific staining techniques on biopsy. Treatment approaches for the underlying plasma cell disorder are similar for both conditions.
-
When should I see a specialist about light chain deposition disease, and how quickly can I be seen privately?
Unexplained kidney impairment or abnormal protein findings on blood or urine tests should prompt haematology and nephrology referral. Private specialist consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.